Lyra Therapeutics Inc Cash Flow-to-Debt Ratio
Lyra Therapeutics Inc cash flow-to-debt ratio. Lyra Therapeutics Inc (LYRA) has a Cash Flow-to-Debt Ratio of -0.13x as of December 2025, meaning its operating cash flow of $-6.07 Million could theoretically repay 0% of its total liabilities ($46.83 Million) in one year. Check LYRA cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Lyra Therapeutics Inc (2018–2025)
Cash flow-to-debt ratio of Lyra Therapeutics Inc from 2018 to 2025. Historical debt coverage capacity for Lyra Therapeutics Inc across 8 annual periods. See how leveraged is Lyra Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.
Lyra Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2018–2025)
Lyra Therapeutics Inc cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Lyra Therapeutics Inc. For the full cash flow conversion analysis, see Lyra Therapeutics Inc cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.62x | $-28.86 Million | $46.83 Million | ▲ +51.8% |
| 2024 | -1.28x | $-70.01 Million | $54.75 Million | ▼ -7.4% |
| 2023 | -1.19x | $-63.30 Million | $53.18 Million | ▲ +19.8% |
| 2022 | -1.49x | $-43.38 Million | $29.21 Million | ▼ -18.2% |
| 2021 | -1.26x | $-25.82 Million | $20.55 Million | ▲ +62.3% |
| 2020 | -3.34x | $-21.14 Million | $6.34 Million | ▼ -85.2% |
| 2019 | -1.80x | $-13.75 Million | $7.63 Million | ▼ -3492.9% |
| 2018 | -0.05x | $-6.64 Million | $132.43 Million | — |